<link rel='stylesheet' href='https//fonts.googleapis.com/css?family=Roboto:400,500,700,400italic|Material+Icons'>
Open Search
SRPT
Sarepta
$
()


  • Sarepta price target raised by $30 at TD Cowen, here's why

    Today - 07:15am
  • Sarepta price target raised by $5 at BofA, here's why

    2/16/2024 - 17:20pm
  • Sarepta Priority Review confirms FDA 'amenability to approval,' says RBC Capital

    2/16/2024 - 10:08am
  • Sarepta announces FDA acceptance of efficacy supplement to Elevidys BLA

    2/16/2024 - 07:15am
  • Sarepta price target raised by $15 at Mizuho, here's why

    2/14/2024 - 06:42am
  • Sarepta price target raised by $47 at Citi, here's why

    2/5/2024 - 10:05am
  • UPS downgraded, Stryker upgraded: Wall Street's top analyst calls

    1/31/2024 - 09:53am
  • Sarepta initiated with bullish view at BMO Capital, here's why

    1/31/2024 - 04:28am
  • Catalent price target raised by $3 at RBC Capital, here's why

    1/30/2024 - 09:37am
  • Sarepta announces data from Part B of MOMENTUM study

    1/29/2024 - 07:31am
  • Sarepta price target lowered by $4 at RBC Capital, here's why

    1/25/2024 - 09:16am
  • Sarepta price target raised by $65 at JPMorgan, here's why

    1/22/2024 - 07:28am
  • Sarepta initiates screening in EMERGENE study

    1/16/2024 - 09:28am
  • Sarepta reports preliminary FY23 net product revenue $1.145B

    1/8/2024 - 11:56am
  • Regenxbio: Sarepta granted summary judgment on invalidity in patent suit

    1/8/2024 - 07:19am
dynamic_feed Breaking News